Every 10-Q that Joint Corp (JYNT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow JYNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JYNT filings page.
The Joint Corp. reported higher profitability while advancing its shift to a franchise‑focused model for the quarter and six months ended June 30, 2026. Continuing‑operations revenue reached $15.2 million for the quarter and $30.0 million year‑to‑date, driven mainly by royalty, advertising and software fees.
Continuing operations produced a quarterly net loss of $0.3 million but year‑to‑date net income of $0.9 million, while discontinued corporate clinics added $1.1 million of net income, bringing total net income to $2.0 million and diluted EPS of $0.14 for the first half of 2026.
The company continued refranchising its corporate clinics, ending the period with 896 franchised and 45 company‑owned or managed clinics, and assets held for sale of $12.3 million. Liquidity remained solid with $23.8 million in cash, cash equivalents and restricted cash, no borrowings outstanding under its credit facility, and share repurchases totaling $1.8 million year‑to‑date.
The Joint Corp. reported first-quarter 2026 results with continuing-operations revenue of $14.8 million, up from $13.1 million a year earlier, and net income of $1.3 million versus $1.0 million.
Continuing operations swung to a $1.1 million profit from a prior-year loss as franchising and fee-based revenues grew while costs stayed controlled. The corporate clinic segment is classified as discontinued operations as the company pursues a major refranchising strategy; revenue from those clinics fell to $9.4 million from $16.9 million, reflecting progress on clinic sales. Cash and cash equivalents were $20.7 million, with total assets of $57.9 million and liabilities of $42.4 million. The company repurchased $1.1 million of stock under its buyback program and ended the quarter with 868 franchised clinics and 943 total clinics in operation.
The Joint Corp. reported Q3 2025 results showing modest top-line growth and a return to profitability. Total revenue was $13.38 million, up from $12.65 million a year ago, driven by higher royalty, franchise, advertising, and software fees as the business shifts toward franchising.
Income from continuing operations was $290,370 versus a loss of $414,383 last year, while discontinued operations contributed $564,639 as the company refranchises and exits company-run clinics. Net income was $855,009 compared with a net loss of $3.17 million in Q3 2024. For the nine months, revenue reached $39.73 million and net income was $1.92 million.
Cash and cash equivalents were $29.70 million at September 30, 2025, up from $25.05 million at year-end. The company repurchased $2.29 million of common stock during the quarter. The network ended the period with 884 franchised clinics and 78 company-owned or managed clinics, for 962 total. As of November 3, 2025, 14,866,192 common shares were outstanding.